NCT01598311View on ClinicalTrials.gov

A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)

PHASE3CompletedINTERVENTIONAL
Enrollment

608

Participants

Timeline

Start Date

May 16, 2012

Primary Completion Date

July 26, 2015

Study Completion Date

August 25, 2015

Conditions
Clostridium Difficile Infection
Interventions
DRUG

CB-183,315

CB-183,315 250 mg white coated tablet over-encapsulated in a size 00 opaque hard gelatin capsule.

DRUG

Vancomycin

Vancomycin hydrochloride 125 mg capsule over-encapsulated in size 00 opaque hard gelatin capsule.

DRUG

Placebo

Placebo size 00 opaque hard gelatin capsules.

All Listed Sponsors
lead

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT01598311 - A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006) | Biotech Hunter | Biotech Hunter